Seronegative Myasthenia Gravis - Efgartigimod IV — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Seronegative Myasthenia Gravis - Efgartigimod IV — Stella

Recruiting

Back to Efgartigimod trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

Canada

University Health Network, Division of Neurology, Toronto General Hospital, Toronto, Ontario

Key details

Phase

Large-scale testing

Sponsor

University Health Network, Toronto

Enrollment target

~30 participants

Started

June 2023

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated September 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov